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Summary
Objectives: To determine the plasma homocysteine and von Willebrand factor levels as markers of endothelial 
dysfunction in rats with diabetes mellitus induced by streptozotocin.
Methods: Thirty-five adult male rats (Rattus norvegicus albinus) (weight between 180-200g) were randomized into three 
groups: control group (n=10), which received no drugs or vehicles; sham group (n=10), which received streptozotocin 
solution; and diabetic group (n=15), which received streptozotocin. Eight weeks after diabetes mellitus induction, 
the animals were weighed and anesthesized; blood samples were collected from abdominal aorta for plasma total 
homocysteine, von Willebrand factor and glucose levels.
Results: The experimental model was reproducible in 100% of animals. The mean plasma homocysteine levels were: 
7.9 µmol/l (control), 8.6µmol/l (sham) and 6.1µmol/l (diabetic), with difference among the groups (p<0.01). Multiple 
comparison analysis among the groups showed that values in the diabetic group were lower than in the sham group 
(p<0.01). The mean von Willebrand factor values were 0.15 U/l (control), 0.16U/l (sham) and 0.18 U/l (diabetic), with 
difference among the groups (p=0.03). The mean value was higher in the diabetic group than in the control group 
(p<0.05). Correlation between homocysteine and von Willebrand factor was not observed in the diabetic group.
Conclusion: Reduced homocysteine levels and increased von Willebrand factor levels were observed in diabetes mellitus 
induced by streptozotocin; nevertheless, there were no correlations between them and with final glucose levels.
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Introduction
Diabetes mellitus (DM), a disease characterized 
fundamentally by a disorder in the metabolism of 
carbohydrates, is usually accompanied by macroangiopathy 
and microangiopathy, peripheral, cranial nerve and autosomal 
neuropathy, which cause isolated or associated major clinical 
complications with a high mortality rate.
In terms of vasculopathy, the endothelium is primarily affected 
and several elements have been related to its dysfunction.
The purpose of this article is to study the possible changes in 
plasma levels of homocysteine (He) and von Willebrand factor 
(vWF), which are known to be related with the pathogenesis 
of endothelial dysfunction, in rats with streptozotocin-induced 
(STZ) diabetes mellitus.
Methods
This is an experimental study involving adult male rats 
(Rattus norvegicus albinus, Rodentia, mammalia) at same 
age range and weight between 180-200g. The animals were 
weighed at the beginning of the experiment and then on 
a weekly basis up to the day they were killed. They were 
randomized into 3 groups: Group I (control): the animals 
continued to receive a normal diet and were allowed free 
water intake; Group II (sham): the animals received only 
the saline solution of STZ (citrate buffer 0.1M, pH = 4.5) 
and remained with the same local and food condition as the 
animals in Group I; Group III (diabetes): received the injection 
of STZ (Sigma® IP). 
DM was induced with intraperitoneal administration of 
STZ (single dose of 60 mg/kg body weight) diluted in 0.3 mL 
of 0.1 M citrate buffer solution1-3. During the first 48 hours, 
diabetic rats were offered glucose solutions (2.5% and 5%) 
which replaced water in order to prevent hypoglycemia due to 
hyperinsulinemia resulting from the destruction of pancreatic 
beta cells. During the first 72 hours after administration of STZ, 
blood glucose was measured every day at the same time to 
prove the method reproducibility; measurements were made 
with Advantage (Roche®) meter by using blood collected from 
a vein puncture in the animal tail. Rats with glucose levels 
≥250 mg/dL were considered diabetic1-5.
Eight weeks after DM induction, the animals were 
weighed, their blood glucose levels were checked and the 
animals underwent general anesthesia with intraperitoneal 
administration of thionembutal (Sigma®) (50 mg/kg body 
weight) for further blood collection and killing. 
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the range of 75-99 mg/dL. The von Willebrand factor was 
determined by Elisa technique using a von Willebrand factor 
kit (DAKO®).
The study was evaluated and duly approved by Research 
Ethics Committee under record No.1341/05. In the statistical 
analysis, in order to assess if the mean variables studied were 
the same in the three groups, we used an analysis of variance 
(ANOVA) with a fixed factor (group) and three levels (control, 
sham and diabetes). For the final blood glucose variable, 
we used reverse transformation to stabilize variance. When 
ANOVA showed that the means in the groups were not 
identical, we used Tukey’s procedure for multiple comparisons 
to identify which groups were responsible for such differences. 
Dispersion diagrams were built and the Pearson correlation 
coefficients were calculated to assess the presence of linear 
association between the variables. The significance level was 
established at 5% in all analyses.
Results
The DM experimental model was reproducible in 100% 
of animals. Table 1 shows the mean, standard deviation, 
median, minimum and maximum values for the variables 
in each group. Figures 1-4 contain box-plots for such 
variables.
Table 1 also presents the descriptive level of analysis 
of variance employed to compare the means in the three 
Blood collection was performed by means of puncture of 
the abdominal aorta and 3 mL of blood were distributed into 
tubes containing EDTA as an anticoagulant agent, followed 
by centrifugation at 3000 rpm. Plasma was aliquotted into 1-
mL vials and stored in a freezer at –20ºC until determination 
of plasma total He levels. The remaining blood was placed 
in a dry tube, centrifuged and the serum was aliquotted into 
1.5-mL vials, and frozen at –20 °C for determination of vWF 
and glucose levels.
Determination of plasma total He was carried out with high 
performance liquid chromatography (HPLC) by fluorimetric 
detection, following a standardized protocol based on the 
methodology described by Pfeiffer et al6 and used by Cruz 
et al7. Plasma underwent 3 stages of preparation: reduction, 
protein precipitation and derivatization. We used the system 
from Shimadzu®, composed of an autoinjector model SIL-10 
Advp, pumps and fluorescence detector model RF – 10AXL. 
Separation was performed with a Prodigy ODS2 column, 
measuring 150 x 3.2 mm and containing 5µm microparticles 
(Phenomenex®) and a pre-column of Adsorbosphere® C18 
measuring  7.5 x 4.6 mm and containing 5µm microparticles 
(Alltech®). Dectection was performed with the detector 
adjusted for excitation at 385 µm and emission at 515 µm. 
Measurement of the initial fasting blood glucose (initial 
BG) and at the end of the experiment (final BG) we used the 
enzymatic-colorimetric method, glucose oxidase/peroxidase 
(GOD PAP-Celm). The reference values were considered in 
Table 1 – Descriptive measurements for initial and final blood glucose (BG), homocysteine (Hc) and von Willebrand factor (vWf)  
in each group, and the ANOVA descriptive level
Control Sham Diabetes Descriptive level
He Mean 7.9 8.6 6.1 <0.01
Standard deviation 2.3 2.2 1.3
Minimum 4.2 6.4 3.2
Median 7.7 7.8 6.3
Maximum 12.0 13.0 8.1
vWF Mean 0.15 0.16 0.18 0.03
Standard deviation 0.3 0.2 0.4
Minimum 0.11 0.13 0.14
Median 0.15 0.15 0.18
Maximum 0.19 0.19 0.26
Initial BG Mean 88.7 88.9 85.1 0.23
Standard deviation 5.9 8.2 5.2
Minimum 80.0 80.0 80.0
Median 90.0 88.0 83.0
Maximum 99.0 101.0 98.0
Final BG Media 85.0 80.9 353.5 <0.01
Standard deviation 7.1 5.0 98.2
Minimum 76.0 75.0 245.0
Median 84.5 79.5 349.0
Maximum 99.0 91.0 561.0
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groups, for each variable. According to this analysis, there 
was no difference among the means of initial blood glucose 
levels in the three groups (p= 0.23). Regarding other 
variables (plasma He, vWF and serum concentration of 
blood glucose on the day of killing), the means were not the 
same in the three groups (p<0.01, p= 0.03 and p<0.01, 
respectively). 
According to Tukey’s procedure for multiple comparisons, 
the mean He was lower in the group of diabetic animals than 
in the control and sham groups; there was no difference 
between the means of control and sham groups (p<0.05). As 
to vWF, the mean was higher in the diabetes group than in the 
control group; no other difference was detected among the 
groups (p<0.05). For final glucose level, the mean was higher 
in the diabetes group than in the control and sham groups, 
and there was no difference between the means of control 
Table 2 - Pearson correlation coefficients among the variables  
studied in each group
Diabetes He vWF¹
vWF 0.13*
Final glucose -0.06* 0.18*
* NS; vWF - von Willebrand factor.
and sham groups (p<0.05).
Table 2 presents the Pearson correlation coefficients among 
the variables studied for the diabetes group. No correlation 
was observed among the variables plasma He, vWF and blood 
glucose at the end of the experiment.
Fig. 1 - Plasma total homocysteine in each group (box-plot). Differences found 
(p<0.05): Diabetes vs Control; Diabetes vs sham.
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Fig. 2 - von Willebrand factor in each group (box-plot). Differences found 
(p<0.05): Diabetes vs Control.
vo
n 
W
ill
eb
ra
nd
 fa
ct
or
Fig. 4 - Final fasting glucose level in each group  (box-plot). Differences found 
(p<0.05): Diabetes vs Control; Diabetes vs sham.
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Fig. 3 - Initial fasting glucose level in each group (box-plot). No difference 
among the means was detected (p=0.23).
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Discussion
DM is a disease responsible for numerous cardiac 
and vascular complications.  Endothelial dysfunction is 
an important element in its pathophysiology and several 
biochemical abnormalities are involved in this condition.
Homocysteine (He) was first reported as a cause of 
atherosclerosis in 19698, and has been gaining more 
importance as a risk factor for coronary artery disease9-15 
with its intriguing possible participation in the pathogenesis 
of endothelial dysfunction. An amino acid formed exclusively 
by demethylation of dietary methionine or by catabolism, 
it contains a thiole group (SH-) and does not participate in 
protein synthesis16. Only 2-5% of free plasma He is found in 
its reduced form and 70-80% is found in the bloodstream 
bound to plasma proteins, especially albumin. 
The prevalence of hyperhomocysteinemia (HHe) is 5-7% 
in the overall population and intermediate levels are found 
in 13-47% of individuals with symptomatic atherosclerotic 
vascular disease17-19. Several publications correlate HHe with 
coronary, cerebral and peripheral artery disease, as well as 
venous thrombosis, and it has shown to be  an important 
cardiovascular risk factor, independent from the others20. 
A meta-analysis involving 27 studies with more than 4000 
patients showed that, for He values higher than 10 µmol/L, 
an increase by 5 µmol/L of circulating He is associated with 
a higher risk of cardiovascular disease. A He increase of 5 
µmmol/L corresponds to an increase by 20 mg/dL in plasma 
total cholesterol, with a higher likelihood of acute myocardial 
infarction21. Graham et al22 concluded that fasting HHe or after 
methionine overload corresponds to a cardiovascular risk that 
is similar to that of hyperlipidemia or smoking, although lower 
than that of systemic hypertension. 
In 1998, Folsom et al23 questioned the participation of 
HHe in the pathophysiology of coronary artery disease in an 
important study. However, their results are not corroborated 
by more recent studies24. 
The pathogenesis of the vascular injury caused by HHe 
includes damage to the endothelial cell, growth of vascular 
smooth muscle, higher platelet adhesion, increased oxidation 
of LDL-cholesterol with deposits in the vessel wall and direct 
activation of the coagulation cascade20.  However, it is still not 
clear by which pathophysiological mechanism He promotes 
the development of atherothrombosis25. 
The endothelium, the main endocrine organ in the 
body, is of great importance in numerous degenerative and 
inflammatory diseases. Among several methods to appraise 
its dysfunction, vWF has been very efficient and presents 
excellent sensitivity. Endothelial cells and megacariocytes 
synthesize, store and secrete vWF. Such secretion increases 
when the endothelial cells are stimulated or damaged, and the 
values can increase by two- to ten-fold in affected individuals. 
The von Willebrand factor binds to collagen and to other 
components of the vascular wall and, therefore, it serves as 
a mediator of platelet adhesion to the subendothelium of 
damaged vessels26. 
Vascular injury exposes the subendothelial collagen matrix, 
which binds to the circulating vWF in the plasma; this, in turn, 
binds to the extracellular platelet membrane glycoproteins 
(GPIb), whose intracellular portion is bound to the filamin of 
the platelet cytoskeleton. This interaction, known as platelet 
adhesion, is enough to trigger two phenomena in the platelets: 
cell contraction and conformational abnormality27-29.
In DM, because of genetic and plasma biochemical factors, 
endothelial dysfunction is early and determines the beginning 
and progression of vascular disease, thus causing diabetic 
microangiopathy and macroangiopathy. In a recent study, Becker 
et al25 aimed to determine to which extent He was associated 
with endothelial dysfunction in diabetic and non diabetic rats, 
and whether such a dysfunction could be estimated by plasma 
vWF levels. They concluded that the relation between He and 
atherothrombosis can not be explained by the association of 
homocysteine and vWF. In the search for an element that can 
be a marker of this damage, vWF starts to have an important 
clinical interest and it can be considered a serum marker of 
endothelial dysfunction in DM. 
For induction of DM, we used STZ in this experiment for 
being the model that represents better reproducibility of results 
as compared with those found in the literature30-35. The results 
of this study show that there are changes in the plasma He and 
vWF levels in DM, due to metabolic abnormalities, among 
which hyperglycemia is the most important.
Similar to the results of the current study (Table 1), the 
studies performed by Jacobs et al36, Wollesen et al37 and 
Veldman et al38 demonstrated lower levels of He in rats with 
experimental diabetes.
Since homocysteine causes direct damage to the endothelium, 
it also stimulates cell proliferation and collagen production, 
maintains a chronic vascular inflammatory process, changes 
the endothelium-dependent arterial relaxation by means of 
nitric oxide, increases oxidative stress, activates coagulation 
factors and inhibits protein C activity. Therefore, we would 
expect to find increased levels of He in diabetes due to the 
extensive endothelial damage. However, in the presence of 
hyperglycemia, there is an increase in glomerular filtration37-38; 
the metabolic changes in He pathway36 result in lower levels, 
which corroborates the assertion that He is a risk factor for 
endothelial dysfunction and not a specific marker of endothelial 
damage in DM. We can infer that normal or increased values 
of He in DM are related with endothelial injury.
The von Willebrand factor has been optimized as a marker 
of endothelial dysfunction. In the current study, its values 
(Table 2) were significantly increased in diabetic rats, which 
make us consider it is an important factor in DM endothelial 
dysfunction.
No correlation between He and vWF (Table 2) has been 
observed; therefore, we conclude that in this experiment the 
relationship between He and possible atherothrombosis in 
diabetic rats can not be explained by the association between 
He and vWF. 
Conclusions
Hemocysteine values were lower in diabetic rats, and could 
trigger or maintain endothelial damage; therefore, it is not a 
marker of its dysfunction. Since vWF is a marker of endothelial 
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dysfunction, its increased levels allow inferring the presence 
of vascular damage in DM. There was no correlation between 
final blood glucose, He and vWF in diabetic rats.
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